Clinical Trials Browser

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04538664 2026-02-25

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 1 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04689828 2026-02-20

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoid

Lymphoma, Follicular

NCT02032823 2026-02-17

OlympiA

Phase 3 Active not recruiting

1,836 enrolled 20 charts 1 FDA

Breast

Breast Neoplasms

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Phase 2 Active not recruiting

124 enrolled 10 charts 1 FDA

Lymphoid

Lymphoma, Mantle-Cell

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03653507 2026-02-06

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04044768 2026-02-06

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

52 enrolled 15 charts 1 FDA

Sarcoma

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04656652 2026-02-05

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Phase 3 Active not recruiting

605 enrolled 14 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

Clinical Trials

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

TOPAZ-1

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

ZUMA-2

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

PEARLS

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

INAVO120

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

MAGNITUDE

AGAVE-201

POSEIDON

NIAGARA

TALAPRO-2

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

KEYNOTE-564

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

IMforte

SEQUOIA

NAPOLI 3

KEYNOTE-B96

CheckMate901

MK-3475-054

DB-06

COLUMBUS

LAURA

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

PAPILLON

innovaTV 301

CLEAR

KEYNOTE-A18

PSMAfore

ROSEWOOD

OlympiA

CheckMate 648

OlympiAD

Spotlight

AMPLITUDE

NETTER-P

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Perseus

IKEMA

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

GLOW

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

MARIPOSA-2

KEYNOTE-826